Overview
This module will explore the changing trends of invasive pneumococcal disease (IPD) in adults, including the evolving landscape of IPD in the post-COVID era, the significance of serotype 3 IPD and the need for protection against it. With the recent availability of 20-valent pneumococcal conjugate vaccine (PCV20) in Hong Kong, this module will also examine how PCV20 compares with the currently available adult pneumococcal vaccines, based on key clinical data and differences in serotype coverages. Lastly, the module will cover updated global and local recommendations for adult pneumococcal vaccinations and PCV20 integration into existing vaccine schedules.
Upon completion of this module, participants should be able to:
PP-PNR-HKG-0267
Pfizer Corporation Hong Kong Limited
21/F, Kerry Centre, 683 King’s Road,
Quarry Bay, Hong Kong